Czech and Slovak Ophthalmology 107 10.31348/2019/1/3 Original article Treatment of Idiopathic Choroidal Neovascular Membrane with Ranibizumab - Our Experience Chrapek Oldřich https://orcid.org/0000-0002-1403-4936 Vostrovská Zuzana Šínová Irena Chrapková Barbora 20 7 2019 1 3

Objective: To evaluate the anatomical and functional outcome of ranibizumab therapy in patients with idiopathic choroidal neovascularization (CNV). File and Methodology: The group consists of 6 patients. Patients were older 18 years but they were under 50 years of age. The monitoring period lasted 12 months. We confirmed active idiopathic CNV in subfoveal position with fluorescein angiography (FAg) and optical coherence tomography (OCT). The activity of idiopathic CNV we demonstrated with leakage of dye by FAg examination. The presence of serous retinal pigment epithelium detachment and / or subretinal fluid and / or intraretinal edema in the form of intraretinal cysts demonstrated activity of CNV on OCT scans. A decrease of the visual acuity under 85 letters was observed at the ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity chart. After the initial administration of ranibizumab a pro re nata regimen was used. We indicated repeated injection of ranibizumab in patients with signs of activity of idiopathic CNV on OCT scans or by FAg. Also we indicated repeated injection of ranibizumab in patients with new loss of visual acuity on the ETDRS visual acuity chart connected with signs of activity of CNV on OCT scans or by FAg. Results: On average, we observed the gain of +11 letters on the ETDRS visual acuity chart after 12 months of the follow-up period. On average we observed reduction of central macular thickness -233μm. At the 12th month of follow-up we observed in all patients of our group only inactive scar without exudation. No serous retinal pigment eithelium detachment, subretinal fluid or intraretinal cysts were observed. Only 3 injections of ranibizumab were administered on average to each patient during the 12 months of the follow-up period. Conclusion: In our study, we observed the positive effect of ranibizumab on the course of idiopathic CNV. With ranibizumab treatment we achieved regression of CNV with resorption of macular edema in all patients of our group. With the disappearance of the activity of idiopathic CNV ranibizumab gives real hope to improve visual acuity.

 idiopathic choroidal neovascular membrane anti-VEGF treatment ranibizumab References Brown, D.M., Michels, M., Kaiser, P.K. et al.: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology, 116, 2009; 1: 57–65.e5. Carneiro, A.M., Silva, R.M., Veludo, M.J. et al.: Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia. Ophthalmologica, 225, 2011; 2:81–88. Cohen, S.Y., Laroche, A., Leguen, Y. et al.: Etiology of choroidal neovascularization in young patients. Ophthalmology, 103,1996; 8: 1241-1244. Derosa, J.T., Yannuzzi, L.A., Marmor, M. et al.: Risk factors for choroidal neovascularization in young patients: a casecontrol study. Doc Ophthalmol, 91,1995; 3: 207–222. Fung, A.E., Lalwani, G.A., Rosenfeld, P.J. et al.: An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration. Am J Ophthalmol, 143, 2007; 4: 566-583. Holz, F.G., Amoaku, W., Donate, J. et al.: Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age related macular degeneration: the SUSTAIN study. Ophthalmology, 118, 2011; 4: 663–671. Houfa, Y., Xiaoyun, F., Jian, M. et al.: Idiopathic Choroidal Neovascularization: Intraocular Inflammatory Cytokines and the Effect of Intravitreal Rinibizumab Treatment. Scientific Reports, 6, 2016, Article number: 31880. Doi:10.1038/ srep31880., Dostupné na: https://www.nature.com/articles/ srep31880 Chuanfeng, F., Qiang, J., Yu, W. et al.: Clinical Efficacy of Intravitreal Ranibizumab in Early and Mid-Idiopathic Choroidal Neovascularization. Journal of Ophthalmology, Volume 2014, Article ID 382702, Dostupné na http://dx.doi. org/10.1155/2014/382702.10.1155/2014/382702 Inagaki, M., Harada, T., Kiribuchi, T. et al.: Subfoveal choroidal neovascularization in uveitid. Ophthalmologica, 2010, 1996; 4: 229 – 233. Klein, R., Peto, T., Bird, A., et al.: The epidemiology of age- -related macular degeneration. Am J Ophthalmol, 137, 2004; 3: 486 – 495. Lai, T.Y.Y., Staurenghi, G., Lanzetta, P. et al.: Efficacy and safety of ranibizumab for the treatment of choroval neovascularization due to uncommon cause. Twelve-Month Results of the Minerva Study. Retina, 0, 2017; 1-14. Sasahara, M., Otani, A., Yodoi, Y. et al.: Circulating hematopoietic stem cells in patients with idiopathic choroidal neovascularization. Invest Ophthalmol Vis Sci, 50, 2009; 4: 1575–1579. Spaide, R.F.: Choroidal neovascularization in younger patients. Curr Opin Ophthalmol, 10, 1999; 3:177–181. Tufail, A., Narendran, N., Patel, P.J. et al.: Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology, 120, 2013; 9: 1944–1945.e1. Tufail, A., Patel, P.J., Sivaprasad, S. et al.: Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond), 27, 2013; 6: 709–715. Wolf, S., Balciuniene, V.J., Laganovska, G. et al.: RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology, 121, 2014; 3: 682–692.e2.